EURETINA 2020 Virtual - Programme Schedule

Programme ScheduleProgramme Overview
EURETINA Sessions Keynotes Symposia Instructional Courses Free Paper Abstracts Poster Abstracts Prize Papers All Days Fri 2nd Sat 3rd Sun 4th Load Favourites

Please note that all times are in Central European Summer Time (CEST)

Programme Filter
timer Loading ... please wait
Fri 02 10:15 - 10:45 CEST

Channel 1

10.15
S. Rizzo ITALY
The restless fight against inherited blindness

 

Fri 02 10:45 - 11:30 CEST
Chairperson(s):
B. Chanana INDIA

Channel 3

10.45
B. Chanana INDIA
Management of dropped IOL and nucleus

10.51
S.J. Chen TAIWAN
Inadvertent globe perforation during local anaesthesia for cataract surgery and its Management

10.57
H. Heimann UK
Retinal detachment in mismanaged cataract surgery: Prevention, etiology, and management

11.03
K. Fong   MALAYSIA
Cystoid macular edema: When and how to treat?

11.09
M. Zinckernagel   SWITZERLAND
Endophthalmitis: early detection, differentiation from sterile reaction, and management

11.15
Discussion

11.30
End of session

 

Fri 02 11:00 - 11:45 CEST
Chairperson(s):
U. Schmidt-Erfurth AUSTRIA,  A. Loewenstein ISRAEL

Channel 1

11.00
U. Schmidt-Erfurth AUSTRIA
Neovascular AMD: AI evidence on novel grounds

11.06
S. Sivaprasad UK
Diabetic retinopathy severity: Diagnostic and therapeutic guidance

11.12
R. Tadayoni FRANCE
Surgery of (pseudo) holes: Standards in macular surgery

11.18
A. Loewenstein ISRAEL
Heads-up surgery: More options than ever

11.24
TBC
The myopia pandemic: The European response

11.30
Discussion

11.45
End of session

Fri 02 11:45 - 12:30 CEST
Chairperson(s):
G. Pertile ITALY, G. Prigione ITALY

Channel 3

11.45
G. Pertile ITALY
Introduction

11.47
G. Prigione ITALY
Strategies to deal with an intraocular foreign body

11.54
G. Caputo FRANCE
Foreign bodies and perforating traumas in children

12.01
H. Mortada 
Management of late complications correlated with foreign body injuries

12.08
G. Pertile ITALY
Pitfalls in removing intraocular foreign bodies

12.15
Discussion

12.30
End of session

 

Fri 02 11:45 - 12:30 CEST
Chairperson(s):
M. Munk SWITZERLAND,  N. Waheed USA, S. Vujosevic ITALY

Channel 2

11.45
S. Vujosevic ITALY
Nomenclature of qualitative and quantitative OCTA parameters

11.53
M. Munk SWITZERLAND
Consensus on OCTA metrics in retinal vascular diseases and standardization of OCTA parameters in clinical trials

12.01
F. Pichi UAE
Consensus on OCTA metrics in inflammatory diseases

12.09
U. Chakravarthy UK
The Unicorn: Expert consensus on OCT A nomenclature in exudative AMD

12.17
Discussion

12.30
End of session

Fri 02 12:00 - 12:45 CEST
Chairperson(s):
A. Laidlaw UK,  J. Garcia-Arumi SPAIN

Channel 1

12.00
B. Corcóstegui SPAIN
Encirclement: what does it do? when to use it?

12.05
J. Garcia-Arumi SPAIN
PVR, when how and what to peel

12.10
T. Williamson UK
Retinectomy in PVR: early vs late

12.15
J.C. Pastor SPAIN
Risks with Tamponade agents

12.20
TBC
Realistic expectations in complex RRD

12.25
Discussion

12.45
End of session

Fri 02 13:45 - 14:30 CEST
Chairperson(s):
D. E. Pelayes ARGENTINA

Channel 3

13.45
M. Batataglia Parodi ITALY
Multimodal diagnostic tools in DME

13.50
R. Cano Hidalgo MEXICO
Angio SS OCT in DME

13.55
V. Chong UK
The role of laser in DME

14.00
D. E. Pelayes argentina
New trends of pharmacotherapy in DME

14.05
F. Fayyad JORDAN
Mastering surgical management

14.10
F. March de Ribot SPAIN
Combining lines in DME and proliferative retinopathy

14.15
Discussion

14.30
End of session

 

Fri 02 13:45 - 14:30 CEST
Chairperson(s):
B. Bodaghi FRANCE, C. Pavesio UK

Channel 2

13.45
B. Bodaghi FRANCE
Overall role of local therapy and indications in NIU-PS

13.50
C. Pavesio UK
Local and/or systemic strategies: what is the best option for each patient?

13.55
Z. Habot-Wilner ISRAEL
Local therapeutic armamentarium: from A to Z

14.00
U. Pleyer GERMANY
Common complications of local therapies and their management

14.05
Q.D. Nguyen USA
Local Treatment in Development for Uveitis

14.10
M. de Smet SWITZERLAND
Best examples of therapeutic management in current practice

14.15
Discussion

14.30
End of session

 

Fri 02 14:00 - 14:45 CEST
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  E. Midena ITALY

Channel 1

14.00
E. Pilotto ITALY
Retinopathy in Type 1 diabetic children

14.06
A. Fawzi USA
Retinal blood flow in diabetic retinopathy

14.12
M. Paques FRANCE
Deferred laser in DME: follow ETDRS or aim for TelCaps?

14.18
N. Bressler USA
Current and future DRCRnet protocols in diabetic retinopathy

14.24
A. Laidlaw UK
Surgical solutions for DR, when to go in

14.30
Discussion

14.45
End of session

Fri 02 14:45 - 15:30 CEST
Chairperson(s):
J. Monés SPAIN

Channel 3

14.45
J. Monés SPAIN
Introduction

14.50
G. Staurenghi ITALY
The new nomenclature for AMD

14.58
K. Csaky USA
The role of functional testing in AMD

15.06
J. Monés SPAIN
New and future treatments for AMD

15.14
Discussion

15.30
End of session

 

Fri 02 14:45 - 15:30 CEST
Chairperson(s):
S. Charles USA, T. Rossi ITALY

Channel 2

14.45
T. Rossi ITALY
Welcome and Introduction

14.48
T. Hassan USA
More options for wide-field viewing — back to the future

14.51
P. Stalmans BELGIUM
First reported clinical results from end-stage RP patients implanted with an innovative 3D- neural interface retinal prosthesis

14.54
S. Charles USA
Medium term PFO for inferior RDs, giant breaks (except superior) and macular patch grafts.

14.57
T. Rossi ITALY
Novel instrument for ILM, amniotic and retinal flap manipulation

14.59
D. Steel UK
Sphere of influence and fluctuations in flow during vitrectomy – effect of cutter design

15.02
M. De Smet  SWITZERLAND
Optimizing subretinal delivery via robotics

15.05
S. Rizzo ITALY
A novel multi-function instrument

15.08
Discussion

15.30
End of session

 

Fri 02 15:00 - 15:45 CEST
Chairperson(s):
S. Wolf SWITZERLAND,  N. Eter GERMANY

Channel 1

15.00
P. Keane UK
Artificial Intelligence in OCT and fundus images: Overview

15.07
T. Peto UK
Artificial Intelligence for DR screening

15.11
R. Tadayoni FRANCE
From DRSS to new imaging and AI

15.15
R. Sznitman SWITZERLAND
Biomarker detection in OCT scans

15.19
S. Sadda USA
Deep learning for assessment of AMD biomarkers

15.23
R. Schwartz UK
Using deep learning to detect reticular pseudodrusen on the UK Biobank – results and implications

15.27
Discussion

15.45
End of session

Fri 02 15:45 - 16:30 CEST
Chairperson(s):
O. Zeitz GERMANY

Channel 3

15.45
T. Jackson UK
Designing, executing and interpreting randomized clinical trials

15.53
L. Kodjikian FRANCE
From randomized clinical trial to real-world: efficacy of VEGF inhibitors

16.01
O. Zeitz GERMANY
Understanding safety data: From adverse events to undesirable effects

16.08
A. Joussen GERMANY
Future developments in retina: scientific, clinical and other challenges for the pipeline

16.15
Discussion

16.30
End of session

Fri 02 15:45 - 16:30 CEST
Chairperson(s):
J. A. Hallak USA, F. G. Holz GERMANY, Maximilian Pfau GERMANY

Channel 2

15.45
N. Hammel USA
ML for predicting conversion to neovascular AMD

15.50
P. Keane UK
Predicting AMD progression using AI

15.55
L. de Sisternes USA
AMD-related biomarker extraction from optical coherence tomography (OCT) and OCT angiography data

16.00
J.A. Hallak  USA
AI in neovascular AMD: prediction of injection requirements

16.05
Joint Discussion – State-of-the-art AI-applications for exudative AMD

16.15
M. Pfau  GERMANY
Beyond RPE-atrophy: novel biomarkers to characterize retinal atrophy progression

16.20
S. Gao  USA
Prediction of disease progression in AMD to improve clinical trial design

16.25
Joint Discussion – Unmet needs and future directions in Geographic Atrophy

16.30
End of session

 

Fri 02 16:00 - 16:45 CEST
Chairperson(s):
K. Rezaei USA,  R. Tadayoni FRANCE

Channel 1

16.00
M. Berrocal PUERTO RICO
Rescue the View

16.01
Discussion

16.04
J. Garcia Arumi SPAIN
Lens Dislocation and Retinal Detachment in Marian Syndrome

16.05
Discussion

16.08
C. Claes BELGIUM
Oops, no way to make sclerotomies

16.09
Discussion

16.12
K. Kadonosono JAPAN
Limiting Phototoxicity During 3D Vitrectomy for Retinitis Pigmentosa

16.13
Discussion

16.16
X. Li CHINA
Air-Fluid Exchange…

16.17
Discussion

16.20
A. Maia BRAZIL
Retinal Detachment with Suprachoroidal Hemorrhage

16.21
Discussion

16.24
G. Pertile ITALY
Subretinal Injection of Membrane Blu Dual

16.25
Discussion

16.28
S. Priglinger GERMANY
Submacular Perfluoron

16.29
Discussion

16.32
S. Rizzo ITALY
Disposable Cryo

16.33
Discussion

16.36
D. Steel UK
Perfluoron Guided Subretinal TPA

16.37
Discussion

16.40
R. Tadayoni FRANCE
TBD

16.41
Discussion

16.45
End of session

Sat 03 08:30 - 09:15 CEST
Chairperson(s):
F. G. Holz GERMANY, G. Staurenghi ITALY, A. Tufail UK

Channel 1

08.30
TBC
New insights from epidemiological studies

08.35
A. Tufail UK
Managing AMD patients: impact of AI-based biomarker detection in OCT scans

08.40
R. Guymer AUSTRALIA
Approaches to slow progression of intermediate AMD

08.45
Discussion

08.52
J. Mones SPAIN
Novel therapeutic approaches for neovascular AMD – better efficacy/longer duration?

08.57
C. Regillo USA
Long-acting drug delivery in nAMD: ARCHWAY phase 3 results

09.02
A. Loewenstein ISRAEL
Improving adherence and outcomes in AMD therapy: Home monitoring

09.07
Discussion

09.15
End of session

Sat 03 08:45 - 09:30 CEST
Chairperson(s):
C. Creuzot-garcher FRANCE, M. Gillies AUSTRALIA

Channel 3

08.45
C. Creuzot-Garcher FRANCE
From Clinical trial to registry: pros and cons

08.53
M. Gillies AUSTRALIA
Long term observational study, the FRB example in AMD

09.01
D. Barthelmes SWITZERLAND
Key learnings from FRB for clinical practice

09.09
V. Daien FRANCE
From registry data to nationwide study

09.17
Discussion

09.30
End of session

 

Sat 03 08:45 - 09:30 CEST
Chairperson(s):
A. Laidlaw UK, S. Saidkasimova UK

Channel 2

Panel: Y. Le Mer FRANCE, K. Krepler AUSTRIA, I. Relimpio SPAIN, M. Romano ITALY

08.45
C. Franco Ruedas SPAIN
Presentation 1: Retinal autograph in large refractory macular hole

08.48
Discussion

08.53
C. Iovino ITALY
Presentation 2: Human amniotic membrane plug in a patient with recurrent macular hole and atrophic AMD: what’s the best surgical approach?

08.56
Discussion

09.01
J.B. Ducloyer FRANCE
Presentation 3: Gene therapy: a new complication

09.04
Discussion

09.09
M. Sommer AUSTRIA
Presentation 4: ”Fiat Lux”- A sleeve for vitrectomy light probe modification

09.12
Discussion

09.17
F. Sabatino UK
Presentation 5: ILM flap for the optic disc pit maculopathy

09.20
Discussion

09.25
Announcement of the winner

09.30
End of session

Sat 03 09:30 - 10:15 CEST
Chairperson(s):
A. Loewenstein ISRAEL,  N. Eter GERMANY

Channel 1

09.30
R. Schlingemann THE NETHERLANDS
New insights in the pathophysiology of diabetic macular edema in vein occlusion

09.36
P. Lanzetta ITALY
The management of macular edema in vein occlusion

09.42
J. Garcia-Arumi SPAIN
The surgical management of resistant cases of vein occlusion

09.48
F. Bandello ITALY
Is OCT-A essential in vein occlusion?

09.54
U. Schmidt-Erfurth AUSTRIA
Artificial intelligence in vascular retinal disease

10.00
Discussion

10.15
End of session

Sat 03 09:45 - 10:30 CEST
Chairperson(s):
A. Grabowska UK, T. Williamson UK

Channel 2

09.45
T. Williamson UK
Introduction and Natural history of RRD

09.49
J. van Meurs THE NETHERLANDS
Pre-operative assessment and management of the macula in RRD

09.53
A. Grabowska UK
Pre-operative management of the macula in PPV for RRD

09.57
D. Yorston UK
Immediate postoperative posturing

10.01
R.J. Hillier UK
Pneumatic retinopexy vs PPV

10.05
T. Williamson UK
Management of the macular displacement and macular folds

10.09
A. Grabowska UK
PVR, retinectomy and the macula

10.13
Discussion

10.30
End of course

Sat 03 09:45 - 10:30 CEST
Chairperson(s):
E. Pilotto ITALY, R. Schumann THE GERMANY

Channel 3

09.45
R. Schumann GERMANY
Premacular membranes in humans: histologic evidence for different cell populations in fibrotic process

09.51
E. Pilotto ITALY
Morphofunctional evaluation in vitreomacular interface abnormalities

09.57
N. Lois UK
Vitreomacular interface abnormalities in diabetic macular oedema

10.03
R. Frisina ITALY
Surgery in idiopathic cases

10.09
M. de Smet NETHERLANDS
Can robotics contribute to the performance of vitreomacular surgery?

10.15
Discussion

10.30
End of session

 

Sat 03 10:30 - 11:15 CEST
Chairperson(s):
J. Garcia-Arumi SPAIN,  J. van Meurs THE NETHERLANDS

Channel 1

10.30
B. Bodaghi FRANCE
Viral retinitis

10.36
A. Adan SPAIN
New strategies with biologics in uveitis 

10.42
F. Pichi UNITED ARAB EMIRATES
OCTA in uveitis

10.48
J. van Meurs THE NETHERLANDS
Earlier antibiotic treatment is the most feasible step to improve treatment of endophthalmitis

10.54
J. Garcia-Arumi SPAIN
Surgical treatment of endophthalmitis

11.00
Discussion

11.15
End of session

Sat 03 10:45 - 11:30 CEST
Chairperson(s):
J. F. Korobelnik FRANCE

Channel 3

10.45
G. Staurenghi ITALY
Overview on OCTA

10.51
J. Figueira PORTUGAL
OCTA in Diabetic Retinopathy

10.57
N. Eter GERMANY
OCTA in AMD

11.03
M. B. Rougier FRANCE
OCT A and optic disc

11.09
J. F. Korobelnik FRANCE
Quantification in OCT-A: what for?

11.15
Discussion

11.30
End of session

Sat 03 10:45 - 11:30 CEST

Channel 2

10.45
Introduction – YOURS committee
C. Dysli SWITZERLAND,
E. de Carvalho UK ,
L. Kuehlewein GERMANY,
R. Mastropasqua ITALY,
Y. Subhi DENMARK,
E. van Dijk THE NETHERLANDS

10.47
C. Iovino ITALY
Photodynamic therapy induced choroidal changes in central serous chorioretinopathy – experience from different countries

10.52
G. Ledesma Gil MEXICO/UK
Don’t throw your fluorescein angiography machine away yet

10.57
M. Bagger DENMARK
The hangman game of uveal melanoma

11.02
R. D’Aloisio ITALY
From smallfield to widefield OCTA in retinal vascular diseases

11.07
T. Nguyen THE NETHERLANDS
Two-year prospective follow-up in patients with CRB1-associated retinal dystrophies: paving the way towards gene therapy

11.12
T. Heeren UK
The end stage of Macular Telangiectasia type 2

11.17
Discussion and announcement of the winner of the Science Slam

11.28
Announcement winner Ophthalmologica lecture

11.30
End of session

Sat 03 12:30 - 13:00 CEST

Channel 1

12.30
R. Spaide USA
Reconsidering Pachychoroid and What it Means

 

Sat 03 13:00 - 13:30 CEST

Channel 1

13.00
M. S. Figueroa SPAIN
Plasma Rich in Growth Factors for Macular Holes in High Myopia

 

Sat 03 13:30 - 14:15 CEST
Chairperson(s):
R. Hillier UK, R. Muni CANADA

Channel 3

13.30
R. Hillier UK
Welcome (including audience poll – ‘How many audience members currently incorporate pneumatic retinopexy into their routine clinical practice?’)

13.32
P. Kertes CANADA
Review of the Pneumatic Retinopexy Trial findings

13.34
R. Hillier UK
Top line findings of the Pneumatic Retinopexy versus Vitrectomy for the Management of Primary Rhegmatogenous Retinal Detachment Outcomes Randomized Trial (PIVOT) and post hoc analyses

13.36
R. Muni CANADA
Top line findings of the Retinal Displacement Detected with Fundus Autofluorescence Imaging following Pneumatic Retinopexy vs Pars Plana Vitrectomy for Rhegmatogenous Retinal Detachment Studies (INTEGRITY and ALIGN)

13.38
R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Principles of intraocular gas

13.42
P. Kertes CANADA
The fundamentals of pneumatic retinopexy technique: Case selection

13.46
R. Muni CANADA, R. Hillier UK
The fundamentals of pneumatic retinopexy technique: Step-by-step surgical technique (‘the PIVOT method’)

13.54
E. Mavrikakis GREECE
The fundamentals of pneumatic retinopexy technique: Management of complications

13.58
R. Hillier UK, R. Muni CANADA, P. Kertes CANADA, E. Mavrikakis GREECE
Practical pearls and pitfalls when starting out: panel ‘round robin’ discussion

14.06
Discussion

14.15
End of session

Sat 03 13:30 - 13:15 CEST
Chairperson(s):
S. Lesnik-Oberstein THE NETHERLANDS

Channel 2

13.30
We now know how to posture patients after detachment surgery

For: D. Yorston UK
Against: R. Hussain UK

Sat 03 13:45 - 14:30 CEST
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  R. Finger GERMANY

Channel 1

13.45
R. Finger GERMANY
AMD risk and progression.

13.52
A. Schuster GERMANY
Glaucoma onset and progression

13.59
T. Peto UK
Diabetic eye diseases (DR & DME) onset, development of treatable stages, visual prognosis

14.06
C. Delcourt FRANCE
Diet and eye disease

14.13
Discussion

14.30
End of session

Sat 03 15:30 - 16:15 CEST
Chairperson(s):
A. Fung AUSTRALIA, W. Mieler USA, F. Sarraf USA

Channel 3

15.30
V. Sadda USA
Case 1

15.34
C. Boon THE NETHERLANDS
Case 2

15.38
R. Dolz-Marco SPAIN
Case 3

15.42
R. Gallego-Pinazo SPAIN
Case 4

15.46
S. Mrejen FRANCE
Case 5

15.50
A. Tan SINGAPORE
Case 6

15.54
S. Yzer NETHERLANDS
Case 7

15.58
Discussion

16.15
End of session

Sat 03 15:30 - 16:15 CEST
Chairperson(s):
F. Bandello ITALY, M. Zarbin USA

Channel 2

15.30
K. Rezaei USA
Zimura trial results

15.38
P. Rosenfeld USA
Apellis trial results

15.46
P. Kaiser USA
Gene therapy for neovascular AMD update

15.54
F. Bandello ITALY
Faricimab update

16.02
Discussion

16.15
End of session

 

Sat 03 15:45 - 16:30 CEST
Chairperson(s):
A. Loewenstein ISRAEL,  A. Tufail UK, S. Wolf SWITZERLAND, F. G. Holz GERMANY

Channel 1

15.45
Impact of COVID on Retina Care: the aftermath

Panel
A. Tufail UK
A. Lowenstein Israel
F. G. Holz GERMANY
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
C. Mariotti ITALY
L. Kodjikian FRANCE
J. Francois Korobelnik FRANCE

15.54
How does safe spacing/PPE affect the delivery of care – can we continue to be cost-effective?

Panel
R. Hamilton UK
S. Wolf SWITZERLAND
J. Garcia-Arumi SPAIN
J. Francois Korobelnik FRANCE

16.03
Should we alter our surgical environment?

Panel
R. Tadayoni FRANCE
A. Laidlaw UK
F. G. Holz GERMANY
J. Garcia-Arumi SPAIN
C. Mariotti ITALY

16.12
Is virtual the new reality? The Good, the Bad and the Ugly – Efficiency of virtual consults, conferences, and teaching

Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
R. Tadayoni FRANCE
E. Midena ITALY

16.21
What have we learned from the COVID-disruption that we should keep?

Panel
F. G. Holz GERMANY
A. Lowenstein Israel
A. Tufail UK
S. Wolf SWITZERLAND

16.30
End of session

Sat 03 16:30 - 17:15 CEST
Chairperson(s):
A. Koh SINGAPORE, R. Martins Da Silva PORTUGAL

Channel 3

16.30
A. Koh SINGAPORE
Introduction

16.31
A. Carneiro PORTUGAL
Clinical presentation: Epidemiology, differences between ethnic groups, genetic factors – CFH, HTRA1 vs others

16.36
M. Falcão PORTUGAL
Diagnosis and differentials: Current diagnostic criteria, Important differential diagnoses

16.41
G. Staurenghi ITALY
Diagnosis and differentials: Multimodal findings on OCT, ICGA, ICGA

16.46
S. Sadda USA
Treatment: PCV Anti-VEGF Monotherapy (PLANET/HAWK/HARRIER)

16.50
R. Silva PORTUGAL
Treatment: Treat and Extend for PCV (Atlantic study)

16.54
A. Koh SINGAPORE
Treatment: Combination therapy (Latest EVEREST data)

16.58
A. Koh SINGAPORE
Treatment: Current Treatment Algorithm based on Data

17.01
Discussion

17.14
R. Silva PORTUGAL
Closing points and summary

17.15
End of session

Sat 03 16:30 - 17:15 CEST
Chairperson(s):
P. Ferrone USA

Channel 2

16.30
K. A. Rezaei USA
Novel Gene Therapy Approaches for Inherited Retinal Diseases

16.35
T. S. Hassan USA
MD Predictors of Endophthalmitis After Intravitreal Injection: A Multivariable Analysis Based on Injection Protocol and Povidone Iodine Strength

16.40
A. Tufail UK
Anti-VEGF: the future is synthetic?

16.45
P. K. Kaiser USA
New anti-VEGF agents: What’s changed, What’s the same

16.50
F. Boscia ITALY
Small Gauge Surgery of Myopic Foveoschisis

16.55
S. Rizzo ITALY
Retinal Detachment: New Observations to Understand an Old Problem

17.00
Discussion

17.15
End of session

 

Sat 03 16:45 - 17:30 CEST
Chairperson(s):
R. Tadayoni FRANCE, J. Garcia-Arumi SPAIN, K. Rezaei USA

Channel 1

16.45
M. Michaelides UK
Phase 1/2 Clinical Trial of AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 9-month Results

16.50
F. G. Holz GERMANY
Zimura A Novel C5 Inhibitor, Significantly Reduces the Mean Rate of Geographic Atrophy Growth in the GATHER1 Clinical Trial

16.55
R. Tadayoni FRANCE
Oculis OCS-01 Phase 2 Study Results: A Topical Therapeutic for DME

17.00
R. Avery USA
RGX-314 Gene Therapy: Ongoing Phase I/IIa Interim Results

17.05
S. Sadda USA
Impact of pegcetocoplan on progression of nascent geographic atrophy in AMD

17.10
R. Tadayoni FRANCE
Investigating adverse events of intraocular inflammation with retinal vasculitis and/or retinal vascular occlusion in patients treated with brolucizumab

17.15
S. Khan UK
A Global Review of Publicly Available Datasets for Ophthalmic Imaging: Recognising Barriers to Access, Usability and Generalisability

17.20
G. Staurenghi ITALY, S. Charles USA, P. Keane UK
Innovation Discussions: 2020 News and Innovation in imaging, surgery, artificial intelligence

17.30
End of session

Sun 04 09:30 - 10:15 CEST
Chairperson(s):
C.C.W. Klaver THE NETHERLANDS,  M. Zinkernagel SWITZERLAND, R. Schlingemann THE NETHERLANDS

Channel 1

09.30
C. C.W. Klaver THE NETHERLANDS
New insights in retinal disease derived from the EyeRisk study

09.37
TBC
Lessons learnt from single cell transcriptomics of the retina

09.44
TBC
Vascular-Glia-Neuron interactions in the retina

09.51
C. Sanchez THE NETHERLANDS
From screen to bedside: how to implement AI in the management of retinal disease?

09.58
Discussion

10.15
End of session

Sun 04 09:45 - 10:30 CEST
Chairperson(s):
M. Forlini ITALY, T. Nikolakopoulos GREECE, V. Reppucci USA

Channel 2

09.45
W. Schrader GERMANY
Decisions in severe ocular trauma: when to reconstruct, give up reconstruction, or refer

09.50
TBC
Post-traumatic Endophthalmitis: clinical cases

09.55
TBC
Traumatic Retinal Detachment

09.59
M. Zarbin USA
Surgery for NLP eyes after open globe injury

10.05
K. Sabti KUWAIT
The Use of Endoscopy in Severe Posterior Segment Trauma

10.10
F. Fayyad JORDAN
Severe Trauma In Children

10.15
M. Mura SAUDI ARABIA
Management of post-traumatic complications

10.20
Live Discussion Q&A; Entire Group

10.30
End of session

Sun 04 09:45 - 10:30 CEST
Chairperson(s):
G. Pertile ITALY, A. Polito ITALY

Channel 3

09.45
G. Pertile ITALY
Introduction

09.47
R. Tadayoni FRANCE
My preferred peeling strategies in myopic foveoschisis and holes: how, when and why

09.54
Discussion

09.57
E. Maggio ITALY
Anatomic and functional outcomes after surgery: what should we tell the patient?

10.04
Discussion

10.07
M. Mete   ITALY
What if the ILM is gone? Surgery for occuring, recurring or persisting holes after peeling

10.14
Discussion

10.17
C. Mateo SPAIN
Posterior retinal detachment in high myopia

10.24
Discussion

10.27
G. Pertile ITALY
Closing remarks and take home messages

10.30
End of session

 

Sun 04 10:30 - 11:15 CEST
Chairperson(s):
R. Tadayoni FRANCE, Xiaoxin Li CHINA

Channel 1

10.30
K. Ohno-Matsui JAPAN
Ultra wide-field imaging of pathologic myopia

10.36
X. Li CHINA
Transmissions of OCT in PIC, PIC-CNV and M-CNV

10.42
L. Lu CHINA
Three years outcome of macular buckling for macularhole and foveoschisis in high myopic eyes

10.48
Y. Ikuno JAPAN
Surgical approach for myopic macular diseases

10.54
T. Ho TAIWAN
Thinking processes and practices in the management of vitreoretinal interface disorders in pathologic myopia

11.00
Discussion

11.15
End of session

Sun 04 10:45 - 11:30 CEST
Chairperson(s):
R. Schlingemann THE NETHERLANDS,  G. Querques ITALY

Channel 2

10.45
D. Sarraf USA
PAMM VS AMN: Brothers in Arms or Strangers in the Night

10.51
S. Sadda USA
PEVAC

10.57
R. Schlingemann THE NETHERLANDS
Retinal vascular abnormalities associated with leakage and hard exudates, Telcaps and others

11.03
B. Leroy BELGIUM
Decision making in rare hereditary retinal disease

11.09
T. Wolfensberger SWITZERLAND
Surgical challenge-subject TBD

11.15
Discussion

11.30
End of session

Sun 04 10:45 - 11:30 CEST
Chairperson(s):
C. Boon THE NETHERLANDS

Channel 3

10.45
E. van Dijk THE NETHERLANDS
Pathogenesis and diagnosis of CSC

10.53
Discussion

10.55
S. Yzer THE NETHERLANDS
Differential diagnosis of CSC

11.03
Discussion

11.05
C. Boon THE NETHERLANDS
Evidence-based treatment of CSC

11.13
Discussion

11.15
Questions & Answers

11.30
End of session

Sun 04 12:30 - 13:15 CEST
Chairperson(s):
J.F. Kiilgaard DENMARK,  H. Heimann UK

Channel 1

12.30
C. Maschi FRANCE
Diagnosis and treatment of peripheral exudative haemorrhagic chorioretinopathy

12.35
H. Annas THE NETHERLANDS
Retinal Hemeangiomas – new insights in genetics

12.39
R. Hussain UK
PDT for choroidal haemangioma – long-term outcomes and treatment of recurrent exudative retinopathy

12.43
Discussion

12.50
E. Midena ITALY
Challenges in radiation induced macula oedema

12.54
H. Heimann UK
Photodynamic therapy of choroidal melanoma

12.58
E. Kilic THE NETHERLANDS
Molecular genetics and clinical implications in uveal melanoma

13.02
TBC
Treatment of Metastatic Uveal Melanoma

13.07
Discussion

13.15
End of session

Sun 04 12:45 - 13:30 CEST
Chairperson(s):
J. Garcia-Arumi SPAIN

Channel 3

12.45
B. Corcostegui SPAIN
Risc factors in Proliferative Vitreoretinopathy

12.51
E. El Rayes EGYPT
Vitreomacular interface. Epiretinal membranes management

12.57
S. Rizzo ITALY
Endotamponades in PVR

13.03
T. Wolfensberger SWITZERLAND
Retinotomy-retinectomy in PVR. When and how

13.09
J. Garcia-Arumi SPAIN
Staining and PFCL. Viscodissection in closed funnel

13.15
Discussion

13.30
End of session

 

Sun 04 12:45 - 13:30 CEST
Chairperson(s):
J. Kim USA, D. Ting SINGAPORE

Channel 2

12.45
R. Spaide USA
Choriocapillaris Imaging: Going Deep

12.50
S. Sadda USA
OCT Imaging: What Else for the Future?

12.55
G. Cheung SINGAPORE
Imaging in Myopia: Seeing Far into the Future

13.00
J. Kim  USA
Tele-Ophthalmology: Where Are We Headed?

13.05
L. Lam USA
Augmented Reality: How will it become a reality?

13.10
D. Ting SINGAPORE
AI and Ophthalmology: Sky is the Limit

13.15
Discussion

13.30
End of session

 

EURETINA 2020 Virtual

Frank Holz

Prof. Frank G. Holz, FEBO, FARVO

University Eye Hospital Bonn
EURETINA President

Dear Colleagues,

We are delighted to announce EURETINA 2020 Virtual, taking place from 2-4 October, and delivering the highest quality scientific content curated by world-renowned experts in the field of retina.

The Virtual Congress will present up to 4 Channels of scientific content, to include EURETINA Sessions & Keynotes on Channel 1, International Symposia on Channel 2, Instructional Courses on Channel 3, as well as a fourth Channel running on Saturday to present the highest scoring Free Papers.

Having extensively researched the most favourable and engaging formats for this new digital landscape, session times have been reduced to 45 minutes, to present engaging, shortened presentations with live discussion throughout.

The virtual Congress will also present a virtual Exhibition, as well as virtual Networking Lounges and the usual programme of industry sponsored Satellite Symposia. We are most grateful to our loyal sponsors for their support in this new endeavour and are glad to be able to still have the opportunity to engage directly with them during the annual meeting.

We very much hope that you will join us at this year’s first virtual EURETINA Congress and encourage you to avail of the reduced registration rates until September 25th.

With very best wishes,

Prof. Frank G. Holz, FEBO, FARVO
President, EURETINA

Registration Information

Do you have a VAT number? If so, please contact registration@euretina.org for information on how to register. Please also contact us if you are a registered business located outside of the EU.

If you are an EURETINA Member or have submitted an abstract, you may already have an account.

If you do not know the login details for this account, please click on the ‘Forgot password’ link on the registration page and they will be sent to you. Alternatively, contact the Registration Department.

Prices are in Euro & listed without VAT
VAT is charged at 20%
EARLY FEE
5 Aug – 25 Sept
LATE FEE
26 Sept – 4 Oct
EURETINA Member 50 65
Non – Member 95 110
Ophthalmic Nurse / Technician* 50 65

*Documentation such as a work ID or verification letter from your hospital is required and must be uploaded during the registration process for approval.

Additional Info Categories Groups Cancellations

Keynote Lectures – EURETINA 2020 Virtual

Richard Spaide USA speakerfeature EURETINA Lecture Richard Spaide USA
Marta S. FigueroaKreissig LectureMarta S. FigueroaSPAIN
Stanislao RizzoGisbert Richard Lecture Stanislao RizzoITALY

src

Safety Review Committee (SRC) Report

Post-marketing reports have highlighted the occurrence of intraocular inflammation (IOI) in association with retinal vasculitis and retinal vascular occlusion with brolucizumab, which differs from the common experience with other approved anti-VEGF agents.

A Safety Review Committee (SRC) consisting of clinical trial, imaging, and uveitis experts as well as Data Monitoring Committee members was established by Novartis to independently review these post-marketing cases.

View Report

Sign up to EURETINA


© EURETINA All rights reserved
Loading please wait